Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | IDO1 | P14902 | 4/20 | 0.55 |
| ▸ | METAP2 | P50579 | 3/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692441 | 1.00 | NOS1 (1.00) | NOS1AXLIDO1METAP2AHR | |
| SCHEMBL10595712 | 0.84 | NOS1 (0.72) | NOS1AXLIDO1METAP2AHR | |
| SCHEMBL24460593 | 0.77 | NOS1 (0.62) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL29563432 | 0.77 | NOS1 (0.62) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL12601112 | 0.76 | NOS1 (0.61) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL907863 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL476854 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277054 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL5951586 | 0.74 | AXL (0.63) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277055 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425727-B | Preparation method of indazole compound of estrogen receptor inhibitor | 深圳扬厉医药技术有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-116425727-A | Preparation method of indole compound serving as estrogen receptor inhibitor | 深圳扬厉医药技术有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023122498-A1 | ONE-STEP OXIDE BATH FOR IMPROVING ADHESION OF POLYMERIC MATERIALS TO METAL SUBSTRATES | MACDERMID, INCORPORATED (US) | 2023-06-29 | — | — | WO | claimed |
| US-20230199972-A1 | One-Step Oxide Bath for Improving Adhesion of Polymeric Materials to Metal Substrates | MACDERMID, INCORPORATED | 2023-06-22 | — | — | US | claimed |
| CN-112876463-B | Intermediate for preparing PD-L1 antagonist and preparation method thereof | 厦门宝太生物科技股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-112876411-A | Compound and application thereof in synthesis of PDL1 antagonist drug molecules | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-112876463-A | Intermediate for preparing PD-L1 antagonist and preparation method thereof | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-111995577-A | Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof | 上海代为化学科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-117050075-B | Biaryl ring BET inhibitor and synthetic method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739671-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-12612387-B2 | RAS inhibitors and methods of using the same | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| CN-1430602-A | Ary-and heteroaryl sulfonates compounds | BAYER AG (DE) | 2003-07-16 | — | — | CN | disclosed |
| EP-1278722-A1 | ARYL AND HETEROARYL SULFONATES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001074763-A1 | ARYL AND HETEROARYL SULFONATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | CHRNA5, CHRNA7, CHRNA3 | NOS1 2550/4885AXL 706/4885IDO1 311/4885 |
| US-12612387-B2 | RAS inhibitors and methods of using the same | KRAS, NRAS, HRAS | NOS1 4331/4885AXL 1563/4885IDO1 4686/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | NOS1 811/4885AXL 4775/4885IDO1 928/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | NOS1 667/4885AXL 879/4885IDO1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.